Search

Your search keyword '"Assmus B"' showing total 209 results
Start Over Author "Assmus B"
209 results on '"Assmus B"'

7. Pulmonary artery pressure-guided therapy in ambulatory patients with symptomatic heart failure: the CardioMEMS European Monitoring Study for Heart Failure (MEMS-HF)

Author

Angermann, C.E. (Christiane), Assmus, B. (Birgit), Anker, S.D. (Stefan D.), Asselbergs, F.W. (Folkert W.), Brachmann, J. (Johannes), Brett, M.-E. (Marie-Elena), Brugts, J.J. (Jasper J.), Ertl, G. (Georg), Ginn, G. (Greg), Hilker, L. (Lutz), Koehler, F. (Friedrich), Rosenkranz, S. (Stephan), Zhou, Q. (Qian), Adamson, P.B. (Philip B.), Böhm, B., Angermann, C.E. (Christiane), Assmus, B. (Birgit), Anker, S.D. (Stefan D.), Asselbergs, F.W. (Folkert W.), Brachmann, J. (Johannes), Brett, M.-E. (Marie-Elena), Brugts, J.J. (Jasper J.), Ertl, G. (Georg), Ginn, G. (Greg), Hilker, L. (Lutz), Koehler, F. (Friedrich), Rosenkranz, S. (Stephan), Zhou, Q. (Qian), Adamson, P.B. (Philip B.), and Böhm, B.

Abstract

Aims: Heart failure (HF) leads to repeat hospitalisations and reduces the duration and quality of life. Pulmonary artery pressure (PAP)-guided HF management using the CardioMEMS™ HF system was shown to be safe and reduce HF hospitalisation (HFH) rates in New York Heart Association (NYHA) class III patients. However, these findings have not been replicated in health systems outside the United States. Therefore, the CardioMEMS European Monitoring Study for Heart Failure (MEMS-HF) evaluated the safety, feasibility, and performance of this device in Germany, The Netherlands, and Ireland. Methods and results: A total of 234 NYHA class III patients (68 ± 11 years, 22% female, ≥1 HFH in the preceding year) from 31 centres were implanted with a CardioMEMS sensor and underwent PAP-guided HF management. One-year rates of freedom from device- or system-related complications and from sensor failure (co-primary outcomes) were 98.3% [95% confidence interval (CI) 95.8–100.0] and 99.6% (95% CI 97.6–100.0), respectively. Survival rate was 86.2%. For the 12 months post- vs. pre-implant, HFHs decreased by 62% (0.60 vs. 1.55 events/patient-year; hazard ratio 0.38, 95% CI 0.31–0.48; P < 0.0001). After 12 months, mean PAP decreased by 5.1 ± 7.4 mmHg, Kansas City Cardiomyopathy Questionnaire (KCCQ) overall/clinical summary scores increased from 47.0 ± 24.0/51.2 ± 24.8 to 60.5 ± 24.3/62.4 ± 24.1 (P < 0.0001), and the 9-item Patient Health Questionnaire sum score improve

Published
2020
Full Text
View/download PDF

10. Differential prognostic accuracy of right ventricular dysfunction, the Seattle heart failure model and the MAGGIC score in patients with severe mitral regurgitation undergoing the MitraClip® procedure

Author

Heyl, S., primary, Luu, B., additional, Wieszner, M., additional, Nikkhoo, A., additional, Seeger, F., additional, Hemmann, K., additional, Assmus, B., additional, Kaess, B., additional, Zeiher, A.M., additional, Walther, C., additional, Fichtlscherer, S., additional, and Honold, J., additional

Published
2020
Full Text
View/download PDF

11. Somatic blood cell mutations at low variant allele frequency in distinct risk genes are associated with increased mortality in patients with chronic ischemic heart failure

Author

Kiefer, K, primary, Cremer, S, additional, Pardali, E, additional, Abou-El-Ardat, K, additional, Kirschbaum, K, additional, Dorsheimer, L, additional, Rasper, T, additional, Assmus, B, additional, Serve, H, additional, Dimmeler, S, additional, Zeiher, A, additional, and Rieger, M, additional

Published
2020
Full Text
View/download PDF

15. Root colonization of different plants by plant-growth-promoting Rhizobium leguminosarum bv. trifolii R39 studied with monospecific polyclonal antisera

Author

Schloter, M., Wiehe, W., Assmus, B., Steindl, H., Becke, H., Hoflich, G., and Hartmann, A.

Subjects
Rhizobium -- Research, Monoclonal antibody probes -- Usage, Enzyme-linked immunosorbent assay -- Research, Rhizosphere -- Analysis, Biological sciences
Abstract

Monospecific polyclonal antisera and immunological techniques were utilized to localize and quantify the Rhizobium leguminosarum bv. trifolii R39 strain in inoculated leguminous and nonleguminous plants. The antisera pab 200/I and pab 200/II were utilized for the detection of the bacterium due to their high affinity to the antigen and absence of cross-reactions with other bacteria in enzyme-linked immunoabsorbent assay. Furthermore, analysis of root colonizations indicated the ability of Rhizobium sp. to efficiently colonize the roots of leguminous and nonleguminous plants.

Published
1997

22. The effect of intracoronary infusion of bone marrow-derived mononuclear cells on all-cause mortality in acute myocardial infarction: rationale and design of the BAMI trial

Author

Mathur A, Arnold R, Assmus B, Bartunek J, Belmans A, Bönig H, Crea F, Dimmeler S, Dowlut S, Fernández-Avilés F, Galiñanes M, Garcia-Dorado D, Hartikainen J, Hill J, Hogardt-Noll A, Homsy C, Janssens S, Kala P, Kastrup J, Martin J et al., A.I. Virtanen -instituutti, and School of Medicine / Clinical Medicine

Abstract

Over the past 13 years bone marrow-derived mononuclear cells (BM-MNCs) have been widely investigated for clinical efficacy in patients following acute myocardial infarction (AMI). These early phase II trials have used various surrogate markers to judge efficacy and, although promising, the results have been inconsistent. The phase III BAMI trial has therefore been designed to demonstrate that intracoronary infusion of BM-MNCs is safe and will significantly reduce the time to first occurrence of all-cause death in patients with reduced left ventricular ejection fraction after successful reperfusion for ST-elevation AMI (powered with the aim of detecting a 25% reduction in all-cause mortality). This is a multinational, multicentre, randomized, open-label, controlled, parallel-group phase III study aiming to enrol approximately 3000 patients in 11 European countries with at least 17 sites. Eligible patients who have impaired left ventricular ejection (≤45%) following successful reperfusion for AMI will be randomized to treatment or control group in a 1:1 ratio. The treatment group will receive intracoronary infusion of BM-MNCs 2–8 days after successful reperfusion for AMI added on top of optimal standard of care. The control group will receive optimal standard of care. The primary endpoint is time from randomization to all-cause death. The BAMI trial is pivotal and the largest trial to date of BM-MNCs in patients with impaired left ventricular function following AMI. The aim of the trial is to provide a definitive answer as to whether BM-MNCs reduce all-cause mortality in this group of patients., published version, peerReviewed

Published
2017

23. Meta-Analysis of Cell-based CaRdiac stUdiEs (ACCRUE) in patients with acute myocardial infarction based on individual patient data

Author

Gyongyosi, M., Wojakowski, W., Lemarchand, P., Lunde, K., Tendera, M., Bartunek, J., Marban, E., Assmus, B., Henry, T.D., Traverse, J.H., Moye, L.A., Surder, D., Corti, R., Huikuri, H., Miettinen, J., Wohrle, J., Obradovic, S., Roncalli, J., Malliaras, K., Pokushalov, E., Romanov, A., Kastrup, J., Bergmann, M.W., Atsma, D.E., Diederichsen, A., Edes, I., Benedek, I., Benedek, T., Pejkov, H., Nyolczas, N., Pavo, N., Bergler-Klein, J., Pavo, I.J., Sylven, C., Berti, S., Navarese, E.P., Maurer, G., ACCRUE Investigators, Department of Cardiology [Vienna], Medizinische Universität Wien = Medical University of Vienna, Third Division of Cardiology, Medical University of Silesia, unité de recherche de l'institut du thorax UMR1087 UMR6291 (ITX), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN), Department of Cardiology, Rikshospitalet-Oslo University Hospital [Oslo], department organization Studies, Boston College (BC), Cedars-Sinai Medical Center, Department of Medicine III, Goethe-Universität Frankfurt am Main, Dpt of Neurology [Minneapolis], University of Minnesota [Twin Cities] (UMN), University of Minnesota System-University of Minnesota System, Minneapolis Heart Institute, University of Minnesota System-University of Minnesota System-Abbott Northwestern Hospital, Coordinating Center for Clinical Trials, The University of Texas Health Science Center at Houston (UTHealth), Cardiocentro Ticino [Lugano], Universität Zürich [Zürich] = University of Zurich (UZH), Milieux aquatiques, écologie et pollutions (UR MALY), Institut national de recherche en sciences et technologies pour l'environnement et l'agriculture (IRSTEA), Medical Research Center Oulu, University of Oulu, Cardiology Department [Ulm], Universität Ulm - Ulm University [Ulm, Allemagne], Clinic of Emergency Medicine, Military Medical Academy [Serbia], Service de cardiologie [Toulouse], Hôpital de Rangueil, CHU Toulouse [Toulouse]-CHU Toulouse [Toulouse], State Research Institute of Circulation Pathology, Department of Drug Design and Pharmacology [Copenhagen] (ILF), Faculty of Health and Medical Sciences, University of Copenhagen = Københavns Universitet (KU)-University of Copenhagen = Københavns Universitet (KU), Asklepios Klinik St. Georg, Cardiology Department [Leiden], Leiden University Medical Center (LUMC), Cardiology Department [Odense], Odense University Hospital (OUH), Cardiology Department [Debrecen], University of Debrecen, Cardiology Department [Târgu Mureș], University of Medicine and Pharmacy of Târgu Mureș, University Clinic for Cardiology, Medical Centre [Budapest], Hungarian Defense Forces -Ministry of Defence [Budapest], Karolinska Institutet [Stockholm], Invasive Cardiology [Pisa], National Research Council Institute of Clinical Physiology (CNR-IFC), Internal Medicine [Düsseldorf], Heinrich Heine Universität Düsseldorf = Heinrich Heine University [Düsseldorf]-Division of Cardiology, Pulmonology and Vascular Medicine, TIME and LateTIME were supported by a grant from the National Heart, Lung, and Blood Institute under the cooperative agreement 5 UM1 HL087318-01. Part of the study was supported by European Union structural funds (Innovative Economy Operational Program POIG.01.01.02-00-109/09-00) to Dr Wojakowski., Medical University of Silesia (SUM), Unité de recherche de l'institut du thorax (ITX-lab), Service Cardiologie [CHU Toulouse], Pôle Cardiovasculaire et Métabolique [CHU Toulouse], Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), University of Copenhagen = Københavns Universitet (UCPH)-University of Copenhagen = Københavns Universitet (UCPH), Lemarchand, Patricia, University of Zurich, Gyongyosi, M, Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), University of Minnesota [Twin Cities], University of Zürich [Zürich] (UZH), Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-CHU Toulouse [Toulouse]-Hôpital de Rangueil, CHU Toulouse [Toulouse], Odense University Hospital, and Heinrich-Heine-Universität Düsseldorf [Düsseldorf]-Division of Cardiology, Pulmonology and Vascular Medicine

Subjects
Male, Time Factors, MESH: Chi-Square Distribution, Databases, Factual, Physiology, analysis, MESH: Myocardial Contraction, Myocardial Infarction, heart failure, Kaplan-Meier Estimate, 030204 cardiovascular system & hematology, MESH: Stroke Volume, Ventricular Function, Left, MESH: Ventricular Function, Left, MESH: Proportional Hazards Models, 0302 clinical medicine, Recurrence, Risk Factors, MESH: Risk Factors, Myocardial infarction, Prospective Studies, MESH: Bone Marrow Transplantation, Stroke, Bone Marrow Transplantation, Randomized Controlled Trials as Topic, MESH: Treatment Outcome, MESH: Aged, 0303 health sciences, Ejection fraction, MESH: Middle Aged, Ventricular Remodeling, Hazard ratio, MESH: Regeneration, Stroke volume, Middle Aged, MESH: Recovery of Function, 3. Good health, MESH: Myocardial Infarction, Treatment Outcome, Cardiology, Female, MESH: Cerebrovascular Disorders, Cardiology and Cardiovascular Medicine, medicine.medical_specialty, MESH: Myocardium, 610 Medicine & health, MESH: Ventricular Remodeling, [SDV.BC]Life Sciences [q-bio]/Cellular Biology, meta, Disease-Free Survival, 11171 Cardiocentro Ticino, 2705 Cardiology and Cardiovascular Medicine, 03 medical and health sciences, stem cells, Internal medicine, medicine, Humans, Regeneration, cardiovascular diseases, Ventricular remodeling, [SDV.BC] Life Sciences [q-bio]/Cellular Biology, outcome assessment, End-systolic volume, MESH: Kaplan-Meier Estimate, 030304 developmental biology, Aged, Proportional Hazards Models, Chi-Square Distribution, MESH: Humans, business.industry, Myocardium, MESH: Time Factors, Stroke Volume, Recovery of Function, 1314 Physiology, medicine.disease, Myocardial Contraction, MESH: Databases, Factual, anterior wall myocardial infarction, MESH: Male, MESH: Prospective Studies, MESH: Recurrence, meta-analysis, Cerebrovascular Disorders, MESH: Randomized Controlled Trials as Topic, Heart failure, MESH: Disease-Free Survival, business, MESH: Female
Abstract

Rationale : The meta-Analysis of Cell-based CaRdiac study is the first prospectively declared collaborative multinational database, including individual data of patients with ischemic heart disease treated with cell therapy. Objective : We analyzed the safety and efficacy of intracoronary cell therapy after acute myocardial infarction (AMI), including individual patient data from 12 randomized trials (ASTAMI, Aalst, BOOST, BONAMI, CADUCEUS, FINCELL, REGENT, REPAIR-AMI, SCAMI, SWISS-AMI, TIME, LATE-TIME; n=1252). Methods and Results : The primary end point was freedom from combined major adverse cardiac and cerebrovascular events (including all-cause death, AMI recurrance, stroke, and target vessel revascularization). The secondary end point was freedom from hard clinical end points (death, AMI recurrence, or stroke), assessed with random-effects meta-analyses and Cox regressions for interactions. Secondary efficacy end points included changes in end-diastolic volume, end-systolic volume, and ejection fraction, analyzed with random-effects meta-analyses and ANCOVA. We reported weighted mean differences between cell therapy and control groups. No effect of cell therapy on major adverse cardiac and cerebrovascular events (14.0% versus 16.3%; hazard ratio, 0.86; 95% confidence interval, 0.63–1.18) or death (1.4% versus 2.1%) or death/AMI recurrence/stroke (2.9% versus 4.7%) was identified in comparison with controls. No changes in ejection fraction (mean difference: 0.96%; 95% confidence interval, −0.2 to 2.1), end-diastolic volume, or systolic volume were observed compared with controls. These results were not influenced by anterior AMI location, reduced baseline ejection fraction, or the use of MRI for assessing left ventricular parameters. Conclusions : This meta-analysis of individual patient data from randomized trials in patients with recent AMI revealed that intracoronary cell therapy provided no benefit, in terms of clinical events or changes in left ventricular function. Clinical Trial Registration: URL: http://www.clinicaltrials.gov. Unique identifier: NCT01098591.

Published
2015
Full Text
View/download PDF

26. Meta-Analysis of Cell-based CaRdiac stUdiEs (ACCRUE) in patients with acute myocardial infarction based on individual patient data

Author

Gyongyosi, M, Wojakowski, W, Lemarchand, P, Lunde, K, Tendera, M, Bartunek, J, Marban, E, Assmus, B, Henry, T D, Traverse, J H, Moye, L A, Surder, D, Corti, R, Huikuri, H, Miettinen, J, Wohrle, J, Obradovic, S, Roncalli, J, Malliaras, K, Pokushalov, E, Romanov, A, Kastrup, J, Bergmann, M W, Atsma, D E, Diederichsen, A, Edes, I, Benedek, I, Benedek, T, Pejkov, H, Nyolczas, N, Pavo, N, Bergler-Klein, J, Pavo, I J, Sylven, C, Berti, S, Navarese, E P, Maurer, G, Gyongyosi, M, Wojakowski, W, Lemarchand, P, Lunde, K, Tendera, M, Bartunek, J, Marban, E, Assmus, B, Henry, T D, Traverse, J H, Moye, L A, Surder, D, Corti, R, Huikuri, H, Miettinen, J, Wohrle, J, Obradovic, S, Roncalli, J, Malliaras, K, Pokushalov, E, Romanov, A, Kastrup, J, Bergmann, M W, Atsma, D E, Diederichsen, A, Edes, I, Benedek, I, Benedek, T, Pejkov, H, Nyolczas, N, Pavo, N, Bergler-Klein, J, Pavo, I J, Sylven, C, Berti, S, Navarese, E P, and Maurer, G

Abstract

RATIONALE: The meta-Analysis of Cell-based CaRdiac study is the first prospectively declared collaborative multinational database, including individual data of patients with ischemic heart disease treated with cell therapy. OBJECTIVE: We analyzed the safety and efficacy of intracoronary cell therapy after acute myocardial infarction (AMI), including individual patient data from 12 randomized trials (ASTAMI, Aalst, BOOST, BONAMI, CADUCEUS, FINCELL, REGENT, REPAIR-AMI, SCAMI, SWISS-AMI, TIME, LATE-TIME; n=1252). METHODS AND RESULTS: The primary end point was freedom from combined major adverse cardiac and cerebrovascular events (including all-cause death, AMI recurrance, stroke, and target vessel revascularization). The secondary end point was freedom from hard clinical end points (death, AMI recurrence, or stroke), assessed with random-effects meta-analyses and Cox regressions for interactions. Secondary efficacy end points included changes in end-diastolic volume, end-systolic volume, and ejection fraction, analyzed with random-effects meta-analyses and ANCOVA. We reported weighted mean differences between cell therapy and control groups. No effect of cell therapy on major adverse cardiac and cerebrovascular events (14.0% versus 16.3%; hazard ratio, 0.86; 95% confidence interval, 0.63-1.18) or death (1.4% versus 2.1%) or death/AMI recurrence/stroke (2.9% versus 4.7%) was identified in comparison with controls. No changes in ejection fraction (mean difference: 0.96%; 95% confidence interval, -0.2 to 2.1), end-diastolic volume, or systolic volume were observed compared with controls. These results were not influenced by anterior AMI location, reduced baseline ejection fraction, or the use of MRI for assessing left ventricular parameters. CONCLUSIONS: This meta-analysis of individual patient data from randomized trials in patients with recent AMI revealed that intracoronary cell therapy provided no benefit, in terms of clinical events or changes in left ventricular fun

Published
2015

29. Acute myocardial infarction activates progenitor cells and increases Wnt signalling in the bone marrow

Author

Assmus, B., primary, Iwasaki, M., additional, Schachinger, V., additional, Roexe, T., additional, Koyanagi, M., additional, Iekushi, K., additional, Xu, Q., additional, Tonn, T., additional, Seifried, E., additional, Liebner, S., additional, Kranert, W. T., additional, Grunwald, F., additional, Dimmeler, S., additional, and Zeiher, A. M., additional

Published
2011
Full Text
View/download PDF

42. Intracoronary infusion of bone marrow-derived mononuclear cells abrogates adverse left ventricular remodelling post-acute myocardial infarction: insights from the reinfusion of enriched progenitor cells and infarct remodelling in acute myocardial infarction (REPAIR-AMI) trial.

Author

Schächinger V, Assmus B, Erbs S, Elsässer A, Haberbosch W, Hambrecht R, Yu J, Corti R, Mathey DG, Hamm CW, Tonn T, Dimmeler S, Zeiher AM, and REPAIR-AMI investigators

Published
2009
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results